CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial – Management of side effects
DOI 10.1055/s-2008-1037650
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Weinmann, H Schulze-Bergkamen, M Schuchmann, C Düber, G Otto, PR Galle, MA Wörns
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Sorafenib (Nexavar®, Bayer Health Care, Germany), a novel multikinase inhibitor, was the first agent to demonstrate a statistically significant improvement in overall survival for patients (pts) with advanced HCC (SHARP trial). Therefore, sorafenib will probably be the first-line treatment for advanced HCC during the next years. In clinical practice, prevention and management of side effects such as diarrhea,…
Zitieren
Zitierempfehlung
A Weinmann, H Schulze-Bergkamen, M Schuchmann, C Düber, G Otto, PR Galle, MA Wörns (2008) Experiences in the treatment of advanced hepatocellular carcinoma (HCC) with sorafenib beyond the SHARP trial – Management of side effects. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-2008-1037650
Mit CareLit weiterarbeiten